{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:23:13Z","timestamp":1789784593491,"version":"4.0.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Biomedical Research Centres in Exeter and Cambridge and AstraZeneca\u2019s Centre for Genomics Research"},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIHR Senior Clinical and Practitioner Award"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220540\/Z\/20\/A"],"award-info":[{"award-number":["220540\/Z\/20\/A"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Loss of response (LoR) is a major limitation of anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease (IBD). It can result from immunogenicity or other, less well-defined mechanisms. Specific HLA alleles have been linked to immunogenicity, but their association with LoR are not fully understood. In this study, we aimed to assess the relationship between HLA alleles and LoR, and investigate the impact of concomitant immunomodulator use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>LoR and sustained response to infliximab or adalimumab were defined in 25\u2009642 IBD patients from the IBD BioResource. We applied multivariable Cox proportional hazards models to assess the effect of HLA alleles on time to LoR. The effect of concomitant immunomodulator use was also evaluated. Significantly associated alleles were further tested in patients treated with ustekinumab and vedolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HLA-DQA1*05:01 was associated with reduced time to LoR in infliximab-treated patients (P\u2009=\u20095.34E-07), while HLA-DQA1*05:05 was associated with reduced time to LoR in adalimumab-treated patients (P\u2009=\u20093.20E-05). Neither allele was associated with LoR to ustekinumab or vedolizumab. Concomitant use of immunomodulators conferred a protective effect against LoR to infliximab and adalimumab in carriers of HLA-DQA1*05:01 and HLA-DQA1*05:05, respectively. However, this protective effect was not observed in adalimumab-treated patients who carried neither allele subtype (P\u2009=\u2009.11).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings highlight distinct associations between HLA-DQA1*05 allele subtypes and time to LoR of infliximab and adalimumab in IBD-treated patients. The protective effect of immunomodulator use is allele-specific for adalimumab. These results provide a rationale for incorporating HLA testing into personalized anti-TNF management to optimize treatment durability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf195","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:25:50Z","timestamp":1764941150000},"source":"Crossref","is-referenced-by-count":4,"title":["HLA-DQA1*05:01 and DQA1*05:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-1057","authenticated-orcid":false,"given":"Qian","family":"Zhang","sequence":"first","affiliation":[{"name":"Genomics of Inflammation and Immunity Group, Human Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus , Hinxton,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6385-6971","authenticated-orcid":false,"given":"Mohammed","family":"Sharip","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospital NHS Foundation Trust , Cambridge,","place":["United Kingdom"]},{"name":"Department of Medicine, University of Cambridge , Cambridge,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-8044","authenticated-orcid":false,"given":"Christopher","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter,","place":["United Kingdom"]},{"name":"University of Exeter IBD Research Group, , Exeter,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1242-616X","authenticated-orcid":false,"given":"Eathar","family":"Shakweh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St Marks Hospital and Academic Institute, Gastroenterology , London,","place":["United Kingdom"]},{"name":"Department of Metabolism, Digestion and Reproduction, Imperial College London , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6467-0631","authenticated-orcid":false,"given":"Miles","family":"Parkes","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cambridge University Hospital NHS Foundation Trust , Cambridge,","place":["United Kingdom"]},{"name":"Department of Medicine, University of Cambridge , Cambridge,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6058-5528","authenticated-orcid":false,"given":"Tariq","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust , Exeter,","place":["United Kingdom"]},{"name":"University of Exeter IBD Research Group, , Exeter,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2025121306115960300_jjaf195-B1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti\u2011TNF treatment failure in anti\u2011TNF\u2011na\u00efve patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121306115960300_jjaf195-B2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA\u2011DQA1*05 carriage associated with development of anti\u2011drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"2025121306115960300_jjaf195-B3","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/ecco-jcc\/jjae006","article-title":"Impact of HLA\u2011DQA1*05 genotype in immunogenicity and failure to treatment with tumour necrosis factor\u2011alpha antagonists in inflammatory bowel disease: a systematic review and meta\u2011analysis","volume":"18","author":"Rodr\u00edguez Alcolado","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2025121306115960300_jjaf195-B4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1053\/j.gastro.2020.03.073","article-title":"Extended analysis identifies drug\u2011specific association of two distinct HLA class\u202fII haplotypes for development of immunogenicity to adalimumab and infliximab","volume":"159","author":"Powell Doherty","year":"2020","journal-title":"Gastroenterology"},{"key":"2025121306115960300_jjaf195-B5","doi-asserted-by":"crossref","first-page":"jjae129","DOI":"10.1093\/ecco-jcc\/jjae129","article-title":"HLA-DQA1*05 associates with anti\u2013tumor necrosis factor immunogenicity and low adalimumab trough concentrations in inflammatory bowel disease patients from the SERENE ulcerative colitis and Crohn\u2019s disease studies","volume":"19","author":"Reppell","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2025121306115960300_jjaf195-B6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/gutjnl-2019-318835","article-title":"IBD BioResource: an open\u2011access platform of 25\u202f000 patients to accelerate research in Crohn\u2019s and colitis","volume":"68","author":"Parkes","year":"2019","journal-title":"Gut"},{"key":"2025121306115960300_jjaf195-B7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/tpj.2013.18","article-title":"HIBAG\u2014HLA genotype imputation with attribute bagging","volume":"14","author":"Zheng","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"2025121306115960300_jjaf195-B8","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"2025121306115960300_jjaf195-B9","author":"Therneau","year":"2024"},{"key":"2025121306115960300_jjaf195-B10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf195\/65779655\/jjaf195.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf195\/65779655\/jjaf195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf195\/65779655\/jjaf195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T11:12:04Z","timestamp":1765624324000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf195\/8371871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf195","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11]]},"article-number":"jjaf195"}}